DERM
Journey Medical Corporation
Price Chart
Latest Quote
$6.22
+0.30 (+5.07%)
Current Price
| Previous Close | $5.92 |
| Open | $6.05 |
| Day High | $6.25 |
| Day Low | $5.83 |
| Volume | 410,485 |
Stock Information
| Shares Outstanding | 21.53M |
| Total Debt | $25.47M |
| Cash Equivalents | $27.22M |
| Revenue | $64.68M |
| Net Income | $-9.59M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $171.26M |
| EPS (TTM) | $-0.37 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $169.51M |
| Sales | $64.68M |
| Income | $-9.59M |
| Book/sh | $1.13 |
| Cash/sh | $1.26 |
| Employees | 58 |
Financial Ratios
| Quick Ratio | 1.38 |
| Current Ratio | 1.72 |
| Debt/Eq | 82.60 |
Returns & Margins
| ROA | -4.49% |
| ROE | -36.62% |
| Gross Margin | 65.44% |
| Operating Margin | -9.35% |
| Profit Margin | -14.82% |
Ownership
| Insider Ownership | 32.31% |
| Institutional Ownership | 55.81% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -103.67 |
| P/S | 2.65 |
| P/B | 5.51 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $13.50 |
Technical Indicators
| SMA20 | $6.13 |
| SMA50 | $5.65 |
| SMA200 | $7.13 |
| RSI | 47.80 |
| ATR | 0.3066 |
| Shares Float | 14.94M |
| Short Float | 23.19% |
| Short Ratio | 13.06 |
| Volatility | 1.10 |
| Rel Volume | 1.86 |
Performance History
| Week | -0.80% |
| Month | +1.14% |
| Quarter | -10.50% |
| 6 Months | -21.07% |
| YTD | -16.51% |
| Year | -1.43% |
| 3 Years | +204.90% |
| 10 Years | -37.17% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $6.22 | 410,500 |
| 2026-06-17 | $5.92 | 429,600 |
| 2026-06-16 | $6.11 | 501,400 |
| 2026-06-15 | $6.34 | 157,100 |
| 2026-06-12 | $6.34 | 165,800 |
| 2026-06-11 | $6.27 | 168,600 |
| 2026-06-10 | $6.07 | 141,200 |
| 2026-06-09 | $6.18 | 205,300 |
| 2026-06-08 | $6.00 | 157,400 |
| 2026-06-05 | $5.97 | 116,400 |
| 2026-06-04 | $6.22 | 125,500 |
| 2026-06-03 | $6.06 | 180,500 |
| 2026-06-02 | $6.02 | 180,500 |
| 2026-06-01 | $6.09 | 278,000 |
| 2026-05-29 | $6.31 | 193,200 |
| 2026-05-28 | $6.20 | 193,000 |
| 2026-05-27 | $5.99 | 140,000 |
| 2026-05-26 | $6.12 | 284,800 |
| 2026-05-22 | $5.96 | 182,700 |
| 2026-05-21 | $6.21 | 213,100 |
| 2026-05-20 | $6.17 | 346,800 |
| 2026-05-19 | $6.15 | 322,800 |
About Journey Medical Corporation
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
đ° Latest News
How The Journey Medical (DERM) Investment Narrative Is Evolving With An Unchanged Valuation Target
Simply Wall St. âĸ 2026-06-03T22:07:40Z
Journey Medical Corporation Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-15T00:25:26Z
Journey Medical Corp (DERM) Q1 2026 Earnings Call Highlights: Revenue Growth and Strategic ...
GuruFocus.com âĸ 2026-05-14T05:01:39ZHere's What Key Metrics Tell Us About Journey Medical (DERM) Q1 Earnings
Zacks âĸ 2026-05-13T22:30:02Z
Journey Medical (DERM) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-05-13T21:55:29Z
Transcript: Journey Medical Q1 2026 Earnings Conference Call
Benzinga âĸ 2026-05-13T21:17:22Z
Journey Medical Corporation (DERM) Reports Q1 Loss, Beats Revenue Estimates
Zacks âĸ 2026-05-13T21:15:02Z
Aurinia Pharmaceuticals (AUPH) Q1 Earnings and Revenues Top Estimates
Zacks âĸ 2026-05-07T15:15:03Z
Zevra Therapeutics (ZVRA) Q1 Earnings and Revenues Surpass Estimates
Zacks âĸ 2026-05-06T22:30:20Z
Will Journey Medical Corporation (DERM) Report Negative Q1 Earnings? What You Should Know
Zacks âĸ 2026-05-06T14:00:04Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $20,836,000 | $20,788,000 | $22,805,000 | $30,775,000 |
| Cost Of Revenue | $20,924,000 | $20,879,000 | $22,893,000 | $30,775,000 |
| Total Revenue | $61,858,000 | $56,134,000 | $79,181,000 | $73,669,000 |
| Operating Revenue | $61,239,000 | $55,134,000 | $59,662,000 | $70,995,000 |
| Expenses | ||||
| Interest Expense | $3,698,000 | $2,700,000 | $1,698,000 | $2,019,000 |
| Total Expenses | $70,030,000 | $74,364,000 | $78,111,000 | $101,186,000 |
| Other Income Expense | $-90,000 | $5,562,000 | $-3,326,000 | $-89,000 |
| Net Non Operating Interest Income Expense | $-3,109,000 | $-1,943,000 | $-1,376,000 | $-1,959,000 |
| Interest Expense Non Operating | $3,698,000 | $2,700,000 | $1,698,000 | $2,019,000 |
| Operating Expense | $49,106,000 | $53,485,000 | $55,218,000 | $70,411,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-11,431,000 | $-14,672,000 | $-3,853,000 | $-29,628,000 |
| Net Interest Income | $-3,109,000 | $-1,943,000 | $-1,376,000 | $-1,959,000 |
| Interest Income | $589,000 | $757,000 | $322,000 | $60,000 |
| Normalized Income | $-11,359,900 | $-19,065,980 | $-1,225,460 | $-29,539,000 |
| Net Income From Continuing And Discontinued Operation | $-11,431,000 | $-14,672,000 | $-3,853,000 | $-29,628,000 |
| Total Operating Income As Reported | $-8,172,000 | $-13,677,000 | $-2,073,000 | $-27,517,000 |
| Net Income Common Stockholders | $-11,431,000 | $-14,672,000 | $-3,853,000 | $-29,628,000 |
| Net Income | $-11,431,000 | $-14,672,000 | $-3,853,000 | $-29,628,000 |
| Net Income Including Noncontrolling Interests | $-11,431,000 | $-14,672,000 | $-3,853,000 | $-29,628,000 |
| Net Income Continuous Operations | $-11,431,000 | $-14,672,000 | $-3,853,000 | $-29,628,000 |
| Pretax Income | $-11,371,000 | $-14,611,000 | $-3,632,000 | $-29,565,000 |
| Special Income Charges | $0 | $5,678,000 | $-3,143,000 | $0 |
| Interest Income Non Operating | $589,000 | $757,000 | $322,000 | $60,000 |
| Operating Income | $-8,172,000 | $-18,230,000 | $1,070,000 | $-27,517,000 |
| Depreciation Amortization Depletion Income Statement | $4,258,000 | $3,424,000 | $3,767,000 | - |
| Depreciation And Amortization In Income Statement | $4,258,000 | $3,424,000 | $3,767,000 | - |
| Amortization Of Intangibles Income Statement | $4,258,000 | $3,424,000 | $3,767,000 | - |
| Gross Profit | $40,934,000 | $35,255,000 | $56,288,000 | $42,894,000 |
| Per Share | ||||
| Diluted EPS | $-0.47 | $-0.72 | $-0.21 | $-1.69 |
| Basic EPS | $-0.47 | $-0.72 | $-0.21 | $-1.69 |
| Other | ||||
| Tax Effect Of Unusual Items | $-18,900 | $1,168,020 | $-698,460 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-3,237,000 | $-13,958,000 | $5,247,000 | $-23,092,000 |
| Total Unusual Items | $-90,000 | $5,562,000 | $-3,326,000 | $-89,000 |
| Total Unusual Items Excluding Goodwill | $-90,000 | $5,562,000 | $-3,326,000 | $-89,000 |
| Reconciled Depreciation | $4,346,000 | $3,515,000 | $3,855,000 | $4,365,000 |
| EBITDA (Bullshit earnings) | $-3,327,000 | $-8,396,000 | $1,921,000 | $-23,181,000 |
| EBIT | $-7,673,000 | $-11,911,000 | $-1,934,000 | $-27,546,000 |
| Diluted Average Shares | $24,497,973 | $20,431,400 | $18,232,422 | $17,531,274 |
| Basic Average Shares | $24,497,973 | $20,431,400 | $18,232,422 | $17,531,274 |
| Diluted NI Availto Com Stockholders | $-11,431,000 | $-14,672,000 | $-3,853,000 | $-29,628,000 |
| Tax Provision | $60,000 | $61,000 | $221,000 | $63,000 |
| Gain On Sale Of Security | $-90,000 | $-116,000 | $-183,000 | $-89,000 |
| Amortization | $4,258,000 | $3,424,000 | $3,767,000 | - |
| Research And Development | $480,000 | $9,857,000 | $7,541,000 | $10,943,000 |
| Selling General And Administration | $44,368,000 | $40,204,000 | $43,910,000 | $59,468,000 |
| Other Special Charges | - | $-5,678,000 | - | - |
| Impairment Of Capital Assets | - | $0 | $3,143,000 | $0 |
Fetched: 2026-06-08
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $4,247,000 | $-11,794,000 | $63,000 | $-10,215,000 |
| Total Assets | $94,589,000 | $80,241,000 | $76,849,000 | $105,160,000 |
| Total Non Current Assets | $27,716,000 | $32,062,000 | $20,394,000 | $27,481,000 |
| Goodwill And Other Intangible Assets | $27,605,000 | $31,863,000 | $20,287,000 | $27,197,000 |
| Other Intangible Assets | $27,605,000 | $31,863,000 | $20,287,000 | $27,197,000 |
| Current Assets | $66,873,000 | $48,179,000 | $56,455,000 | $77,679,000 |
| Other Current Assets | $3,376,000 | $3,212,000 | $3,588,000 | $3,309,000 |
| Inventory | $9,624,000 | $14,431,000 | $10,206,000 | $14,159,000 |
| Receivables | $29,783,000 | $10,231,000 | $15,222,000 | $28,208,000 |
| Accounts Receivable | $29,783,000 | $10,231,000 | $15,222,000 | $28,208,000 |
| Allowance For Doubtful Accounts Receivable | $-200,000 | $-600,000 | $-500,000 | $-400,000 |
| Gross Accounts Receivable | $29,983,000 | $10,831,000 | $15,722,000 | $28,608,000 |
| Cash Cash Equivalents And Short Term Investments | $24,090,000 | $20,305,000 | $27,439,000 | $32,003,000 |
| Cash And Cash Equivalents | $24,090,000 | $20,305,000 | $27,439,000 | $32,003,000 |
| Other Non Current Assets | - | - | $6,000 | $95,000 |
| Non Current Deferred Assets | - | - | - | - |
| Non Current Deferred Taxes Assets | - | - | - | - |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $1,187,000 | $4,574,000 | - | - |
| Total Debt | $25,396,000 | $25,080,000 | $14,730,000 | $22,965,000 |
| Long Term Debt And Capital Lease Obligation | $25,295,000 | $24,997,000 | $14,631,000 | $19,934,000 |
| Long Term Debt | $25,277,000 | $24,879,000 | $14,622,000 | $19,826,000 |
| Current Debt And Capital Lease Obligation | $101,000 | $83,000 | $99,000 | $3,031,000 |
| Current Debt | - | - | - | $2,948,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $62,737,000 | $60,172,000 | $56,499,000 | $88,178,000 |
| Total Non Current Liabilities Net Minority Interest | $25,295,000 | $24,997,000 | $14,631,000 | $21,346,000 |
| Current Liabilities | $37,442,000 | $35,175,000 | $41,868,000 | $66,832,000 |
| Payables And Accrued Expenses | $29,575,000 | $27,965,000 | $30,958,000 | $49,706,000 |
| Interest Payable | $398,000 | $404,000 | $22,000 | $160,000 |
| Payables | $11,181,000 | $18,012,000 | $20,412,000 | $39,645,000 |
| Other Payable | $1,805,000 | $1,374,000 | $2,015,000 | $2,627,000 |
| Total Tax Payable | $70,000 | $60,000 | $53,000 | $35,000 |
| Income Tax Payable | $70,000 | $60,000 | $53,000 | $35,000 |
| Accounts Payable | $8,851,000 | $16,050,000 | $18,149,000 | $36,983,000 |
| Other Current Liabilities | - | $625,000 | $3,360,000 | $2,829,000 |
| Current Deferred Liabilities | - | - | $0 | $4,991,000 |
| Other Non Current Liabilities | - | - | - | $1,412,000 |
| Tradeand Other Payables Non Current | - | - | - | - |
| Equity | ||||
| Common Stock Equity | $31,852,000 | $20,069,000 | $20,350,000 | $16,982,000 |
| Total Equity Gross Minority Interest | $31,852,000 | $20,069,000 | $20,350,000 | $16,982,000 |
| Stockholders Equity | $31,852,000 | $20,069,000 | $20,350,000 | $16,982,000 |
| Retained Earnings | $-98,458,000 | $-87,027,000 | $-72,355,000 | $-68,502,000 |
| Other | ||||
| Ordinary Shares Number | $27,144,655 | $22,153,610 | $19,323,952 | $17,765,700 |
| Share Issued | $27,144,655 | $22,153,610 | $19,323,952 | $17,765,700 |
| Tangible Book Value | $4,247,000 | $-11,794,000 | $63,000 | $-10,215,000 |
| Invested Capital | $57,129,000 | $44,948,000 | $34,972,000 | $39,756,000 |
| Working Capital | $29,431,000 | $13,004,000 | $14,587,000 | $10,847,000 |
| Capital Lease Obligations | $119,000 | $201,000 | $108,000 | $191,000 |
| Total Capitalization | $57,129,000 | $44,948,000 | $34,972,000 | $36,808,000 |
| Additional Paid In Capital | $130,307,000 | $107,094,000 | $92,703,000 | $85,482,000 |
| Capital Stock | $3,000 | $2,000 | $2,000 | $2,000 |
| Common Stock | $3,000 | $2,000 | $2,000 | $2,000 |
| Long Term Capital Lease Obligation | $18,000 | $118,000 | $9,000 | $108,000 |
| Current Capital Lease Obligation | $101,000 | $83,000 | $99,000 | $83,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $5,589,000 | $3,378,000 | $3,374,000 | $2,586,000 |
| Current Provisions | $2,177,000 | $3,124,000 | $4,077,000 | $3,689,000 |
| Current Accrued Expenses | $18,394,000 | $9,953,000 | $10,546,000 | $10,061,000 |
| Dueto Related Parties Current | $455,000 | $528,000 | $195,000 | $413,000 |
| Net PPE | $111,000 | $199,000 | $101,000 | $189,000 |
| Gross PPE | $111,000 | $199,000 | $101,000 | $189,000 |
| Other Properties | $111,000 | $199,000 | $101,000 | $189,000 |
| Inventories Adjustments Allowances | $-996,000 | $-513,000 | $-305,000 | $-429,000 |
| Finished Goods | $7,389,000 | $11,381,000 | $4,987,000 | $7,739,000 |
| Work In Process | $174,000 | $367,000 | $884,000 | $395,000 |
| Raw Materials | $3,057,000 | $3,196,000 | $4,640,000 | $6,454,000 |
| Line Of Credit | - | - | $0 | $2,948,000 |
Fetched: 2026-06-08
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-12,441,000 | $-24,127,000 | $240,000 | $-33,534,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-12,441,000 | $-9,127,000 | $5,240,000 | $-13,534,000 |
| Cash Flow From Continuing Operating Activities | $-12,441,000 | $-9,127,000 | $5,240,000 | $-13,534,000 |
| Operating Gains Losses | - | $-1,125,000 | - | - |
| Investing Activities | ||||
| Investing Cash Flow | $0 | $-15,000,000 | $-5,000,000 | $-20,000,000 |
| Cash Flow From Continuing Investing Activities | $0 | $-15,000,000 | $-5,000,000 | $-20,000,000 |
| Capital Expenditure | - | $-15,000,000 | $-5,000,000 | $-20,000,000 |
| Net Other Investing Changes | - | - | - | $-20,000,000 |
| Financing Activities | ||||
| Financing Cash Flow | $16,226,000 | $16,993,000 | $-4,804,000 | $16,456,000 |
| Cash Flow From Continuing Financing Activities | $16,226,000 | $16,993,000 | $-4,804,000 | $16,456,000 |
| Net Other Financing Charges | $-75,000 | $-50,000 | $-471,000 | $-585,000 |
| Issuance Of Capital Stock | - | - | $4,494,000 | $0 |
| Net Common Stock Issuance | - | - | $4,494,000 | $0 |
| Common Stock Issuance | - | - | $4,494,000 | $0 |
| Net Preferred Stock Issuance | - | - | - | $0 |
| Preferred Stock Issuance | - | - | - | $0 |
| Other | ||||
| Repayment Of Debt | $-625,000 | $-1,250,000 | $-51,948,000 | $-7,864,000 |
| Issuance Of Debt | $16,359,000 | $17,877,000 | $47,494,000 | $24,763,000 |
| Interest Paid Supplemental Data | $3,238,000 | $2,011,000 | $1,127,000 | $993,000 |
| Income Tax Paid Supplemental Data | $50,000 | $125,000 | $181,000 | $168,000 |
| End Cash Position | $24,090,000 | $20,305,000 | $27,439,000 | $32,003,000 |
| Beginning Cash Position | $20,305,000 | $27,439,000 | $32,003,000 | $49,081,000 |
| Changes In Cash | $3,785,000 | $-7,134,000 | $-4,564,000 | $-17,078,000 |
| Proceeds From Stock Option Exercised | $567,000 | $416,000 | $121,000 | $142,000 |
| Net Issuance Payments Of Debt | $15,734,000 | $16,627,000 | $-4,454,000 | $16,899,000 |
| Net Long Term Debt Issuance | $15,734,000 | $16,627,000 | $-1,506,000 | $14,763,000 |
| Long Term Debt Payments | $-625,000 | $-1,250,000 | $-21,000,000 | $-5,000,000 |
| Long Term Debt Issuance | $16,359,000 | $17,877,000 | $19,494,000 | $19,763,000 |
| Net Intangibles Purchase And Sale | $0 | $-15,000,000 | $-5,000,000 | $-20,000,000 |
| Purchase Of Intangibles | $0 | $-15,000,000 | $-5,000,000 | $-20,000,000 |
| Change In Working Capital | $-11,899,000 | $-3,766,000 | $-1,655,000 | $6,187,000 |
| Change In Other Current Liabilities | $-82,000 | $-96,000 | $-83,000 | $-95,000 |
| Change In Other Current Assets | $0 | $6,000 | $0 | $55,000 |
| Change In Payables And Accrued Expense | $2,881,000 | $-4,302,000 | $-17,797,000 | $10,734,000 |
| Change In Accrued Expense | $10,070,000 | $-2,210,000 | $606,000 | $-3,636,000 |
| Change In Interest Payable | $-6,000 | $382,000 | $-138,000 | $160,000 |
| Change In Payable | $-7,189,000 | $-2,092,000 | $-18,403,000 | $14,370,000 |
| Change In Account Payable | $-7,199,000 | $-2,099,000 | $-18,421,000 | $14,343,000 |
| Change In Tax Payable | $10,000 | $7,000 | $18,000 | $27,000 |
| Change In Income Tax Payable | $10,000 | $7,000 | $18,000 | $27,000 |
| Change In Prepaid Assets | $-164,000 | $376,000 | $-279,000 | $-871,000 |
| Change In Inventory | $4,807,000 | $-4,225,000 | $3,953,000 | $1,744,000 |
| Change In Receivables | $-19,341,000 | $4,475,000 | $12,551,000 | $-5,380,000 |
| Changes In Account Receivables | $-19,341,000 | $4,475,000 | $12,551,000 | $-5,380,000 |
| Other Non Cash Items | $466,000 | $307,000 | $709,000 | $833,000 |
| Stock Based Compensation | $6,288,000 | $6,098,000 | $2,606,000 | $4,425,000 |
| Asset Impairment Charge | $-211,000 | $516,000 | $3,578,000 | $284,000 |
| Depreciation Amortization Depletion | $4,346,000 | $3,515,000 | $3,855,000 | $4,365,000 |
| Depreciation And Amortization | $4,346,000 | $3,515,000 | $3,855,000 | $4,365,000 |
| Amortization Cash Flow | $4,258,000 | $3,424,000 | $3,767,000 | $4,277,000 |
| Amortization Of Intangibles | $4,258,000 | $3,424,000 | $3,767,000 | $4,277,000 |
| Depreciation | $88,000 | $91,000 | $88,000 | $88,000 |
| Net Income From Continuing Operations | $-11,431,000 | $-14,672,000 | $-3,853,000 | $-29,628,000 |
| Net Short Term Debt Issuance | - | $0 | $-2,948,000 | $2,136,000 |
| Short Term Debt Payments | - | $0 | $-30,948,000 | $-2,864,000 |
| Short Term Debt Issuance | - | $0 | $28,000,000 | $5,000,000 |
| Deferred Tax | - | - | - | $0 |
| Deferred Income Tax | - | - | - | $0 |
| Gain Loss On Investment Securities | - | - | - | - |
Fetched: 2026-06-08